The medication is still in the clinical trial process and is not approved by the FDA
From a contemporary clinical perspective, these findings also align with the recently proposed cardiovascularkidneymetabolic (CKM) syndrome framework, which emphasizes the interconnected pathophysiology of metabolic dysfunction, CV disease, and kidney disease across a continuum of risk
So for you to be like, Im going to do a 12 year randomized controlled trial of seed oils, its going to be hard to get the people, you know, get all those box checked like you might not be publishing a paper for a while
Journal of Pain Research, 12 , 13411351
10.1016/j.jep.2023.117282 57 QuX.LiuB.WangL.LiuL.ZhaoW.LiuC.et al (2023)